Alzheimer’s disease research moves too slowly, forcing patients to wait a decade or more for a single drug trial to finish.
A first-of-its-kind clinical trial launched across the UK aims to cut years from that search by testing multiple potential treatments simultaneously. The Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial, known as AD-SMART, starts with two existing medicines already prescribed for other conditions.
Researchers will examine whether metformin, typically used for Type 2 diabetes, and atomoxetine, used for attention-deficit/hyperactivity disorder, can lessen memory and thinking problems. Both drugs may help reduce brain inflammation, which is a primary driver of neurodegeneration.
“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works,” Paresh Malhotra, professor of clinical neurology and chief investigator of AD-SMART, said.
The platform trial aims to recruit 1,200 patients aged 55 or over with a confirmed diagnosis of Alzheimer’s disease or mixed Alzheimer’s and vascular dementia. Alzheimer’s is the most common type of dementia, currently affecting around 600,000 people in the UK.
Organizers expect up to 20 NHS sites to open across the UK over the next 12 to 18 months, with more than 30 planned overall. Initial participants have already enrolled at the Cambridgeshire and Peterborough NHS Foundation Trust and the Surrey and Borders Partnership NHS Foundation Trust.
Additional sites at Imperial College Healthcare NHS Trust, the Anne Rowling Regenerative Neurology Clinic in Edinburgh, and Southampton are also open. The adaptive design allows researchers to quickly drop treatments that show no promise and introduce new drugs as they become available.
Heather Ransome, 67, received her Alzheimer’s diagnosis in 2024 and enrolled as one of the trial’s first participants. She and her partner previously enjoyed cruises and coach holidays in retirement before her diagnosis shifted their daily routine.
“I’m not the sort of person who gets upset, but being told you have Alzheimer’s is quite upsetting,” Ransome said. “There weren’t many treatment options available, and the one drug I was offered has been around for many years.”
She added that participating gives her hope for the future despite uncertainties about whether she receives the active treatment or a placebo. The AD-SMART team expects to finish evaluating the first round of repurposed drugs in 2030.
Keep reading